End-of-day quote
Korea S.E.
18:00:00 2024-06-13 EDT
|
5-day change
|
1st Jan Change
|
1,144
KRW
|
-1.63%
|
|
-2.80%
|
-6.61%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
34,621
|
63,614
|
79,325
|
60,663
|
44,486
|
35,387
|
Enterprise Value (EV)
1 |
60,175
|
75,655
|
88,805
|
65,850
|
39,118
|
46,334
|
P/E ratio
|
-5.11
x
|
-4.71
x
|
-36.9
x
|
-26.8
x
|
53.1
x
|
-29.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.23
x
|
1.95
x
|
2.01
x
|
1.54
x
|
1.02
x
|
0.61
x
|
EV / Revenue
|
2.14
x
|
2.32
x
|
2.25
x
|
1.67
x
|
0.9
x
|
0.8
x
|
EV / EBITDA
|
-23.9
x
|
16.2
x
|
31.6
x
|
26.4
x
|
11.3
x
|
9.92
x
|
EV / FCF
|
-14.5
x
|
-
|
-53.6
x
|
-21.6
x
|
-78
x
|
21.8
x
|
FCF Yield
|
-6.89%
|
-
|
-1.87%
|
-4.63%
|
-1.28%
|
4.6%
|
Price to Book
|
1.31
x
|
2.34
x
|
2.66
x
|
1.95
x
|
1.26
x
|
1.06
x
|
Nbr of stocks (in thousands)
|
16,216
|
25,965
|
27,591
|
28,887
|
28,887
|
28,887
|
Reference price
2 |
2,135
|
2,450
|
2,875
|
2,100
|
1,540
|
1,225
|
Announcement Date
|
21-12-17
|
21-03-22
|
21-03-22
|
22-03-22
|
23-03-21
|
24-03-20
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
28,131
|
32,559
|
39,524
|
39,347
|
43,703
|
57,919
|
EBITDA
1 |
-2,515
|
4,663
|
2,807
|
2,496
|
3,467
|
4,668
|
EBIT
1 |
-5,066
|
2,024
|
663.5
|
266.7
|
1,155
|
713.7
|
Operating Margin
|
-18.01%
|
6.22%
|
1.68%
|
0.68%
|
2.64%
|
1.23%
|
Earnings before Tax (EBT)
1 |
-6,632
|
126.1
|
-736.6
|
-395.9
|
666.5
|
-1,764
|
Net income
1 |
-6,632
|
-12,786
|
-2,064
|
-2,258
|
849.6
|
-1,184
|
Net margin
|
-23.58%
|
-39.27%
|
-5.22%
|
-5.74%
|
1.94%
|
-2.04%
|
EPS
2 |
-418.2
|
-520.0
|
-78.00
|
-78.49
|
29.00
|
-40.98
|
Free Cash Flow
1 |
-4,144
|
-
|
-1,657
|
-3,049
|
-501.8
|
2,130
|
FCF margin
|
-14.73%
|
-
|
-4.19%
|
-7.75%
|
-1.15%
|
3.68%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
45.62%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-12-17
|
21-03-22
|
21-03-22
|
22-03-22
|
23-03-21
|
24-03-20
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
25,554
|
12,041
|
9,480
|
5,187
|
-
|
10,947
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
5,368
|
-
|
Leverage (Debt/EBITDA)
|
-10.16
x
|
2.582
x
|
3.377
x
|
2.079
x
|
-
|
2.345
x
|
Free Cash Flow
1 |
-4,144
|
-
|
-1,657
|
-3,049
|
-502
|
2,130
|
ROE (net income / shareholders' equity)
|
-26.8%
|
-
|
-4.61%
|
-2.4%
|
1.86%
|
-1.73%
|
ROA (Net income/ Total Assets)
|
-5.25%
|
-
|
0.51%
|
0.22%
|
0.86%
|
0.42%
|
Assets
1 |
126,410
|
-
|
-404,906
|
-1,044,071
|
98,844
|
-282,814
|
Book Value Per Share
2 |
1,635
|
1,045
|
1,082
|
1,078
|
1,223
|
1,161
|
Cash Flow per Share
2 |
118.0
|
191.0
|
328.0
|
382.0
|
682.0
|
471.0
|
Capex
1 |
859
|
2,710
|
5,269
|
2,414
|
503
|
1,522
|
Capex / Sales
|
3.05%
|
8.32%
|
13.33%
|
6.13%
|
1.15%
|
2.63%
|
Announcement Date
|
21-12-17
|
21-03-22
|
21-03-22
|
22-03-22
|
23-03-21
|
24-03-20
|
|
1st Jan change
|
Capi.
|
---|
| -6.61% | 23.88M | | +21.01% | 8.91B | | +21.62% | 3.6B | | -5.56% | 3.04B | | +13.68% | 1.67B | | -5.27% | 1.23B | | -29.81% | 1.16B | | -31.11% | 1.15B | | -22.47% | 1.01B | | -12.32% | 916M |
Veterinary Drugs
|